Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

donati family vineyard, inc. - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic, hand sanitizer hand sanitizer to help reduce bacteria that potentially can cause disease. for use when soap and water are not available. - in children less than 2 months of age - on open skin wounds stop use and ask a doctor if irritation or rash occurs. these may be signs of a serious condition.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

aurora bioscience pty ltd - 36405 - blood rocker, blood donation - the blood mixer enables the mixing of donated blood with anticoagulant via means of gentle and continuous rocking. the scale enables the desired volume of blood to be collected before the donation line is sealed.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

terumo bct australia pty ltd - 36405 - blood rocker, blood donation - used in the collection of blood for the purpose of mixing anticoagulant and blood and controls the blood donation volume based on weigth.

Europska Unija - engleski - EMA (European Medicines Agency)

roche registration gmbh - epoetin beta - kidney failure, chronic; anemia; cancer; blood transfusion, autologous - antianemic preparations - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients;treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy;increasing the yield of autologous blood from patients in a pre-donation programme. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anaemia (hb 10 - 13 g/dl [6.21 - 8.07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).

Australija - engleski - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 16666.67 iu/ml - injection - excipient ingredients: threonine; polysorbate 20; urea; water for injections; dibasic sodium phosphate dodecahydrate; glutamic acid; leucine; sodium chloride; calcium chloride dihydrate; monobasic sodium phosphate; phenylalanine; glycine; isoleucine - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 20000 iu/ml - injection - excipient ingredients: polysorbate 20; monobasic sodium phosphate; sodium chloride; urea; isoleucine; glycine; threonine; calcium chloride dihydrate; glutamic acid; dibasic sodium phosphate dodecahydrate; phenylalanine; leucine; water for injections - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 16666.67 iu/ml - injection - excipient ingredients: glutamic acid; leucine; isoleucine; polysorbate 20; water for injections; dibasic sodium phosphate dodecahydrate; urea; monobasic sodium phosphate; phenylalanine; threonine; calcium chloride dihydrate; glycine; sodium chloride - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 13333.33 iu/ml - injection - excipient ingredients: leucine; phenylalanine; polysorbate 20; glycine; urea; water for injections; sodium chloride; calcium chloride dihydrate; monobasic sodium phosphate; threonine; glutamic acid; isoleucine; dibasic sodium phosphate dodecahydrate - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 10000 iu/ml - injection - excipient ingredients: monobasic sodium phosphate; glycine; polysorbate 20; leucine; threonine; water for injections; isoleucine; calcium chloride dihydrate; phenylalanine; urea; glutamic acid; dibasic sodium phosphate dodecahydrate; sodium chloride - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - epoetin beta, quantity: 6666.66 iu/ml - injection - excipient ingredients: calcium chloride dihydrate; dibasic sodium phosphate dodecahydrate; water for injections; glutamic acid; isoleucine; urea; monobasic sodium phosphate; polysorbate 20; glycine; phenylalanine; leucine; sodium chloride; threonine - neorecormon is indicated for the treatment of anaemia associated with chronic kidney disease (ckd) in patients on dialysis and symptomatic patients not yet undergoing dialysis. to increase the yield of autologous blood from patients in pre-donation programme initiated to avoid the use of homologous blood. for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks. for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate.